CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 53 enrolled
Drug / intervention
Test tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02246166
NCT02246166Phase 4Completed

A Double-Blind, Randomised, Placebo-Controlled, Parallelgroup, Single-Dose Study to Evaluate Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza Over a 4 Hour Period

GlaxoSmithKline·interventional·Posted Sep 22, 2014·Updated Sep 14, 2016

In Brief

A Phase 4 clinical trial evaluating Test tablet and Placebo for Common Cold. Completed, enrolled 53 participants across 2 sites.

Detailed Summary

This phase IV multi-centre, randomised, double-blind, placebo-controlled, parallel-group, single-dose study will assess the efficacy and tolerability of the active tablets versus placebo in participants suffering from cold and influenza. Eligible participants will be randomly assigned to one of 2 treatment groups (active or placebo tablets) and enter a four-hour (hr) treatment phase. Each participant will be administered only once during each study period. Participants will use a questionnaire to record the symptom severity scores as described, as well as time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesChina

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 22, 2014
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.8 years ago

Interventions

Test tabletdrug

The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity

Placeboother

The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity